Patient, disease, and transplant characteristics of recipients presenting early and late graft failure after CBT for either thalassemia or SCD
| UPN . | Age at CBT . | Diagnosis . | Clinical status at CBT . | HLA . | Conditioning . | GVHD prophylaxis . | Nucleated cell dose × 107/kg . | Chimerism and second transplants . | Outcome and survival . |
|---|---|---|---|---|---|---|---|---|---|
| 54 | 11 y 5 mo | SCD | Cerebral vasculopathy | Matched | BU (16 mg/kg) CY (200 mg/kg) + ATG | CsA + MTX | 4.0 | AR at day + 28 Allogeneic BMT with the same donor at day +39 (CY 100 mg/kg + procarbazine 36 mg/kg + ATG) | Alive with disease + 5 y 5 mo |
| 69 | 1 y 6 mo | Thal | Pesaro class 1 | Matched | BU (16 mg/kg) CY (200 mg/kg) TT (10 mg/kg) | CsA | 7.7 | Nonengraftment Autologous BM infusion at day +46 without preparative regimen | Alive with disease + 5 y 7 mo |
| 99 | 2 y 2 mo | Thal | Pesaro class 2 | Matched | BU (16 mg/kg) CY (200 mg/kg) + ATG | CsA + MTX | 2.3 | Day +25 AR | Alive with disease + 5 y 6 mo |
| 289 | 5 y 6 mo | Thal | Pesaro class 2 | Mismatch in A | BU (16 mg/kg) CY (200 mg/kg) + ATG | CsA + MTX | 8.0 | Day +30 AR Allogeneic BMT with the same donor at 1 y 5 mo (CY 200 mg/kg + BU; 16 mg/kg + ALG) AR after BMT | Alive with disease + 3 y 7 mo |
| 294 | 2 y 3 mo | Thal | Pesaro class 2 | Matched | BU (16 mg/kg) CY (200 mg/kg) + ATG | CsA + MTX | 5.0 | Day +34 AR Allogeneic BMT with the same donor at 1 y 4 mo (CY 200 mg/kg + BU; 16 mg/kg + ALG) | Alive without disease + 3 y 6 mo |
| 350 | 3 y 0 mo | Thal | Pesaro class 2 | Matched | BU (14 mg/kg) CY (180 mg/kg) | CsA | 10.0 | Day +90 AR | Alive with disease + 2 y 7 mo |
| 98 | 2 y 4 mo | Thal | Pesaro class 1 | Matched | BU (14 mg/kg) CY (200 mg/kg) | CsA + MTX | 3.9 | Day +38, mixed chimerism day +150 AR Allogeneic BMT with the same donor at 2 y (CY 200 mg/kg + BU; 16 mg/kg + ALG) | Alive without disease + 3 y 9 mo |
| 63 | 5 y 0 mo | Thal | Pesaro class 2 | Matched | BU (14 mg/kg) CY (120 mg/kg) | CsA | 1.2 | Day +28, full donor Day +100, mixed chimera Day +165 AR Allogeneic BMT with the same donor at 3 y (BU 16 mg/kg, CY 200 mg/kg, TT 8 mg/kg) | Alive without disease + 5 y 7 mo |
| UPN . | Age at CBT . | Diagnosis . | Clinical status at CBT . | HLA . | Conditioning . | GVHD prophylaxis . | Nucleated cell dose × 107/kg . | Chimerism and second transplants . | Outcome and survival . |
|---|---|---|---|---|---|---|---|---|---|
| 54 | 11 y 5 mo | SCD | Cerebral vasculopathy | Matched | BU (16 mg/kg) CY (200 mg/kg) + ATG | CsA + MTX | 4.0 | AR at day + 28 Allogeneic BMT with the same donor at day +39 (CY 100 mg/kg + procarbazine 36 mg/kg + ATG) | Alive with disease + 5 y 5 mo |
| 69 | 1 y 6 mo | Thal | Pesaro class 1 | Matched | BU (16 mg/kg) CY (200 mg/kg) TT (10 mg/kg) | CsA | 7.7 | Nonengraftment Autologous BM infusion at day +46 without preparative regimen | Alive with disease + 5 y 7 mo |
| 99 | 2 y 2 mo | Thal | Pesaro class 2 | Matched | BU (16 mg/kg) CY (200 mg/kg) + ATG | CsA + MTX | 2.3 | Day +25 AR | Alive with disease + 5 y 6 mo |
| 289 | 5 y 6 mo | Thal | Pesaro class 2 | Mismatch in A | BU (16 mg/kg) CY (200 mg/kg) + ATG | CsA + MTX | 8.0 | Day +30 AR Allogeneic BMT with the same donor at 1 y 5 mo (CY 200 mg/kg + BU; 16 mg/kg + ALG) AR after BMT | Alive with disease + 3 y 7 mo |
| 294 | 2 y 3 mo | Thal | Pesaro class 2 | Matched | BU (16 mg/kg) CY (200 mg/kg) + ATG | CsA + MTX | 5.0 | Day +34 AR Allogeneic BMT with the same donor at 1 y 4 mo (CY 200 mg/kg + BU; 16 mg/kg + ALG) | Alive without disease + 3 y 6 mo |
| 350 | 3 y 0 mo | Thal | Pesaro class 2 | Matched | BU (14 mg/kg) CY (180 mg/kg) | CsA | 10.0 | Day +90 AR | Alive with disease + 2 y 7 mo |
| 98 | 2 y 4 mo | Thal | Pesaro class 1 | Matched | BU (14 mg/kg) CY (200 mg/kg) | CsA + MTX | 3.9 | Day +38, mixed chimerism day +150 AR Allogeneic BMT with the same donor at 2 y (CY 200 mg/kg + BU; 16 mg/kg + ALG) | Alive without disease + 3 y 9 mo |
| 63 | 5 y 0 mo | Thal | Pesaro class 2 | Matched | BU (14 mg/kg) CY (120 mg/kg) | CsA | 1.2 | Day +28, full donor Day +100, mixed chimera Day +165 AR Allogeneic BMT with the same donor at 3 y (BU 16 mg/kg, CY 200 mg/kg, TT 8 mg/kg) | Alive without disease + 5 y 7 mo |
Total doses are given in parentheses.
AR indicates autologous reconstitution; Thal, thalassemia.